Financials data is unavailable for this security.
Cash flow in TWDView more
In 2023, cash reserves at Tanvex BioPharma Inc fell by 405.48m. Cash Flow from Financing totalled 1.08bn or 1,757.90% of revenues. In addition the company used 1.43bn for operations while cash used for investing totalled 83.57m.
Cash flow per share | -10.64 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.01 |
---|---|
Tangible book value per share | 8.98 |
More ▼
Balance sheet in TWDView more
Current ratio | 3.64 |
---|---|
Quick ratio | 3.32 |
Total debt/total equity | 1.18 |
---|---|
Total debt/total capital | 0.5405 |
More ▼